Johnson & Johnson (NYSE:JNJ – Get Free Report) had its price objective cut by investment analysts at Morgan Stanley from $174.00 to $171.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has an “equal weight” rating on the stock. Morgan Stanley’s target price suggests a potential upside of 12.28% from the company’s current price.
Several other research analysts have also recently commented on JNJ. Royal Bank of Canada initiated coverage on Johnson & Johnson in a research report on Wednesday, October 4th. They set an “outperform” rating and a $178.00 price target for the company. TheStreet upgraded Johnson & Johnson from a “c+” rating to a “b+” rating in a research note on Monday, August 21st. JPMorgan Chase & Co. upped their price objective on Johnson & Johnson from $175.00 to $180.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. HSBC began coverage on Johnson & Johnson in a research note on Wednesday, September 6th. They issued a “hold” rating and a $175.00 price objective on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday. Eight analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Johnson & Johnson has an average rating of “Hold” and a consensus price target of $169.19.
View Our Latest Stock Analysis on JNJ
Johnson & Johnson Stock Down 0.3 %
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.62 by $0.18. The company had revenue of $25.53 billion during the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a return on equity of 36.71% and a net margin of 36.32%. Johnson & Johnson’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.59 earnings per share. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.11 earnings per share for the current fiscal year.
Insider Activity at Johnson & Johnson
In related news, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction on Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the transaction, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the business. BlackRock Inc. raised its position in shares of Johnson & Johnson by 1.4% in the 1st quarter. BlackRock Inc. now owns 201,491,567 shares of the company’s stock worth $31,231,193,000 after acquiring an additional 2,688,798 shares in the last quarter. State Street Corp increased its position in Johnson & Johnson by 1.1% in the 2nd quarter. State Street Corp now owns 141,833,756 shares of the company’s stock valued at $23,476,323,000 after buying an additional 1,568,633 shares in the last quarter. Moneta Group Investment Advisors LLC increased its position in Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after buying an additional 54,326,454 shares in the last quarter. Geode Capital Management LLC increased its position in Johnson & Johnson by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 49,697,798 shares of the company’s stock valued at $8,203,608,000 after buying an additional 990,298 shares in the last quarter. Finally, Morgan Stanley increased its position in Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after buying an additional 4,521,062 shares in the last quarter. 68.40% of the stock is owned by institutional investors.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
See Also
- Five stocks we like better than Johnson & Johnson
- What Does the Consumer Price Index Measure?
- 3 High Dividend Stocks To Beat Treasury Yields
- Dividend Tax Calculator
- United Airlines Shares Fall Despite Solid Quarter
- What is the Hang Seng index?
- Housing Starts Up, Homebuilders Down as Mortgage Rates Soar
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
